IntroductionTo verify our hypothesis that psoriatic arthritis (PsA) is mainly genetically predetermined and distinct from psoriasis (PsO), we use the TriNetX database to investigate whether intrinsic factors outweigh externals in PsA emergence in PsO patients.MethodsWe conducted three retrospective cohort studies utilizing information from the TriNetX network, whether (a) PsO patients with type 2 diabetes mellitus (DM) face an elevated risk of developing PsA compared to those without type 2 DM; (b) PsO patients who smoke face a higher risk of PsA; and (c) PsO patients with type 2 DM who smoke are more likely to develop PsA than those who do not smoke.ResultsPsO patients with type 2 DM exhibited an elevated risk of developing PsA [hazard ratio (HR), 1.11; 95% CI 1.03–1.20], with the combined outcome demonstrating a heightened HR of 1.31 (95% CI 1.25–1.37). PsO patients with a smoking history exhibited an elevated risk of developing PsA (HR, 1.11; 95% CI 1.06–1.17), with the combined outcome demonstrating a heightened HR of 1.28 (95% CI 1.24–1.33). PsO patients with type 2 DM and a history of smoking were not found to be associated with an increased risk of developing PsA (HR, 1.05; 95% CI 0.92–1.20). However, the combined result revealed a higher risk of 1.15 (95% CI 1.06).DiscussionThese findings suggested that intrinsic factors outweigh external factors in PsA emergence in PsO patients. Further studies may focus on genetic disparities between PsO and PsA as potential risk indicators rather than solely on phenotypic distinctions.

Network of healthcare organizations, together with data partners in Brazil, South Korea, and Japan, to bring clinical facts on more than 250 million patients around the world. Federated model so users of this data are ensured new patients, observations, and results every day, all harmonized to standard terminology like ICD-10 and LOINC without any data wrangling required at the point of care. The raw data is not available to authors of papers and papers in medicine are being retracted.

Values for Kaplan-Meier survival analysis in patients with IO treatment.

RationaleObesity hypoventilation syndrome (OHS) is often underdiagnosed, with significant morbidity and mortality. Bicarbonate, as a surrogate of arterial carbon dioxide, has been proposed as a screening tool for OHS. Understanding the predictors of serum bicarbonate could provide insights into risk factors for OHS. We hypothesized that the bicarbonate levels would increase with an increase in body mass index (BMI), since the prevalence of OHS increases with obesity.MethodsWe used the TriNetX Research Network, an electronic health record database with de-identified clinical data from participating healthcare organizations across the United States, to identify 93,320 adults without pulmonary or advanced renal diseases who had serum bicarbonate and BMI measurements within 6 months of each other between 2017 and 2022. We used linear regression analysis to examine the associations between bicarbonate and BMI, age, and their interactions for the entire cohort and stratified by sex. We also applied a non-linear machine learning algorithm (XGBoost) to examine the relative importance of age, BMI, sex, race/ethnicity, and obstructive sleep apnea (OSA) status on bicarbonate.ResultsThis cohort population was 56% women and 72% white and 80% non-Hispanic individuals, with an average (SD) age of 49.4 (17.9) years and a BMI of 29.1 (6.1) kg/m2. The mean bicarbonate was 24.8 (2.8) mmol/L, with higher levels in men (mean 25.2 mmol/L) than in women (mean 24.4 mmol/L). We found a small negative association between bicarbonate and BMI, with an expected change of −0.03 mmol/L in bicarbonate for each 1 kg/m2 increase in BMI (p < 0.001), in the entire cohort and both sexes. We found sex differences in the bicarbonate trajectory with age, with women exhibiting lower bicarbonate values than men until age 50, after which the bicarbonate levels were modestly higher. The non-linear machine learning algorithm similarly revealed that age and sex played larger roles in determining bicarbonate levels than the BMI or OSA status.ConclusionContrary to our hypothesis, BMI is not associated with elevated bicarbonate levels, and age modifies the impact of sex on bicarbonate.

Multivariable analysis for overall survival in patients with metastatic renal cell carcinoma receiving first-line tyrosine kinase inhibitors or immune checkpoint inhibitors.

Values for Kaplan-Meier survival analysis in patients with TKI treatment.

ObjectiveTo explore the associations between the use of immune checkpoint inhibitors (ICIs) and the risk of developing uveitis among cancer patients.MethodsCancer patients who received ICI therapy and a comparison group of cancer patients who did not receive ICI therapy were retrospectively recruited from the TriNetX electronic heath-record registry. The outcome of interest was the development of new-onset uveitis. Propensity score matching based on a 1:1 ratio was conducted in order to reduce bias. Multi-variate cox proportional hazard models and Kaplan Meier method were also utilized to assess for the risk of uveitis among cancer patients who received ICI therapy.Results71931 cancer patients (54.7% male; 76.5% white; mean age at index 63.6 ± 12.2 years) who received ICI treatment (ICI group) and 71931 cancer patients (54.7% male; 77% white; mean age at index 63.5 ± 12.4 years) who never received ICI (comparison group) were recruited. Associated Kaplan-Meier curves showed significantly increased uveitis risk among the ICI group for all follow-up years (p

This is the Mendeley Supplementary File (including eMethods, Supplementary Tables and Supplementary Figures) of the study entitled "Human Papillomavirus Infection Increases Risk of New-Onset Prurigo Nodularis: A Multi-Center Retrospective Cohort Study Using Global and US Electronic Medical Records of TriNetX network" by Shuo-Yan Gau, Shao-Wei Lo, Yung-Fang Tu, Wen-Chieh Liao, Yu-Jung Su, Hui-Chin Chang, Torsten Zuberbier, Martin Metz and Shiu-Jau Chen for publication in the Journal of the American Academy of Dermatology.

A retrospective cohort study was conducted using the TriNetX Global Collaborative Network, a federated database comprising de-identified electronic health records from 142 healthcare organizations (HCOs). The database was queried on March 13, 2025, to identify patients diagnosed with gastroesophageal reflux disease (GERD). Patients were stratified into two cohorts based on proton pump inhibitor (PPI) exposure. The GERD+PPI cohort included patients with a diagnosis of GERD (ICD-10: K21) who had ≥2 prescriptions for a PPI (omeprazole, esomeprazole, pantoprazole, lansoprazole, dexlansoprazole, or rabeprazole) within 5 years prior to the index date. The GERD control cohort included GERD patients with no history of PPI use, defined as no recorded prescriptions for any listed PPIs at any time. Patients were excluded in the risk analysis if they had a history of cutaneous fungal infections, including onychomycosis, tinea corporis, tinea pedis, tinea cruris, or cutaneous candidiasis. Additional exclusions included a history of systemic antifungal use (fluconazole, terbinafine, itraconazole) within 1 day prior to the index date or a history of immunodeficiency conditions, including HIV (ICD-10: B20), solid organ transplantation, or primary immunodeficiency disorders (ICD-10: D80-D84). Cohorts were propensity score-matched (1:1) to minimize confounding, using variables including age, sex, race/ethnicity, diabetes, obesity, immunosuppression, and concurrent medication use. Standardized mean differences (SMDs) were used to assess balance between matched cohorts. The primary outcome was the incidence of cutaneous fungal infections following PPI use. Risk ratios (RR) with 95% confidence intervals (CIs) were calculated using logistic regression. A p-value <0.05 was considered statistically significant. All statistical analyses were conducted within the TriNetX platform.

This table contains data gathered from TriNetX and compares patients with a diagnosis of xanthelasma to patients with a diagnosis of a benign facial lesion after propensity matching to compensate for differences in age at index event, sex, race, and ethnicity.

Supplemental Methods This study utilized a retrospective cohort design leveraging data from the TriNetX research network, which aggregates electronic health records (EHRs) from 97 healthcare organizations (HCOs). The analysis compared two patient cohorts based on cardiovascular disease (CVD) status, both of whom had been diagnosed with skin cancers, including malignant melanoma (ICD-10: C43), squamous cell carcinoma (C44.92), or basal cell carcinoma (C44.91), and underwent Mohs micrographic surgery (CPT: 17311). The CVD cohort included patients with a concurrent diagnosis of cardiovascular disease, including hypertension (ICD-10: I10-I15), hypertensive crisis (I16), or ischemic heart disease (I20-I25), whereas the non-CVD cohort consisted of patients with similar skin cancer diagnoses and Mohs procedures but without any history of these cardiovascular conditions. The study population was limited to patients whose diagnoses and procedures occurred between January 1, 2015, and December 31, 2023. Patients with an index event occurring more than 20 years prior to the study period were excluded. The index event was defined as the date of the first recorded visit (TNX:Visit) associated with both the skin cancer diagnosis and the Mohs micrographic surgery procedure. A follow-up visit (CVD f/u) was required within six months after the initial visit to ensure patients remained engaged with healthcare services and to capture subsequent cardiovascular events. The time window for outcomes assessment began one day after the index event and extended 30 days and 3-months postoperatively. The primary outcomes included acute myocardial infarction (AMI; ICD-10: I21) and stroke (ICD-10: I63.9). Patients who had a documented history of these outcomes before the study time window were excluded from the risk analysis and survival analysis. To minimize confounding, propensity score matching (PSM) was performed at a 1:1 ratio between the CVD and non-CVD cohorts. Matching variables included age, sex, race, ethnicity, comorbid conditions (hypertension, diabetes, chronic kidney disease, hyperlipidemia, obesity), medication use (anticoagulants, beta-blockers, lipid-lowering agents), and laboratory values (e.g., tobacco smoking status). After matching, each cohort consisted of 27,758 patients. The study employed multiple statistical approaches to compare outcomes between the cohorts. Risk analysis was performed to calculate risk differences, risk ratios, and odds ratios for AMI and stroke. Kaplan-Meier survival analysis was conducted to assess differences in survival probability, applying censoring to account for patients lost to follow-up. Number of instances analysis was used to quantify the frequency of AMI and stroke occurrences within the 30-day and 3-month time window.

Analysis was performed after propensity score matching for age and gender at the index event.

Library of Wroclaw University of Science and Technology scientific output (DONA database)

Cox regression analysis of overall survival for patients with visceral metastases.

Flow chart for Fungal PPI TriNetX Study

Values for Kaplan-Meier survival analysis in prostate cancer patients with lymph node and visceral metastases.

This retrospective cohort study utilized electronic health records from the TriNetX database. A total of 502 NHL patients were included, categorized into CAR-T R+ (receiving CAR-T and radiotherapy) and CAR-T R- (receiving CAR-T and chemotherapy only) groups, balanced through propensity score matching. The primary outcome was four-year mortality risk. Secondary outcomes included emergency visits, organ failure, sepsis, cardiovascular events, inflammation over four years, and acute reactions (Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)) measured over one month.

Studies conflict on the significance of burn-induced coagulopathy. We posit that burn-induced coagulopathy is associated with injury severity in burns. Our purpose was to characterize coagulopathy profiles in burns and determine relationships between % total burn surface area (TBSA) burned and coagulopathy using the International Normalized Ratio (INR). Burned patients with INR values were identified in the TriNetX database and analyzed by %TBSA burned. Patients with history of transfusions, chronic hepatic failure, and those on anticoagulant medications were excluded. Interquartile ranges for INR in the burned study population were 1.2 (1.0–1.4). An INR of ≥ 1.5 was used to represent those with burn-induced coagulopathy as it fell outside the 3rd quartile. The population was stratified into subgroups using INR levels

Baseline characteristics for patients with visceral and bone metastatic prostate cancer.